lysosomal protein transmembrane 4 betaGenealiases: LAPTM4beta · LC27
Q-omics provides the consensus-scored LAPTM4B profile across patient tissues and cancer cell-line models. LAPTM4B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LAPTM4B is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, LAPTM4B RNA expression shows 19,459 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where LAPTM4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAPTM4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAPTM4B survival associations across molecular data types. LAPTM4B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAPTM4B RNA expression–survival associations across cancer types. High LAPTM4B expression shows unfavorable associations in UVM, ACC, LIHC, HNSC, CESC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LAPTM4B RNA expression.
This table summarizes LAPTM4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LAPTM4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAPTM4B shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUAD, COAD, LIHC and LUSC. The HNSC box plot shows higher LAPTM4B RNA expression in tumor versus normal tissue (log2 FC = +1.843, t-test p < 0.001).
This table shows molecular features associated with LAPTM4B in patient tissues and cancer cell lines. In patient samples, LAPTM4B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LAPTM4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
